Teneligliptin (MP513; trade name Tenelia in Japan) is a novel, potent, orally bioavailable and long-lasting dipeptidyl peptidase-4 (DPP-4) inhibitor; it competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM. Chronic teneligliptin treatment at doses between 0.1 and 3.0 μmol/L does not reduce cell viability of HUVECs, but decreases HG-stress markers and increases heme oxygenase-1 (HMOX1) gene expression in HUVEC cells incubated under hyperglycemia. Teneligliptin is an approved drug for the treatment of type 2 diabetes mellitus in Japan.

纯度：≥98%

CAS：760937-92-6